Richard Schutter - Bausch Health Independent Director
| BHC Stock | USD 8.45 0.24 2.76% |
Director
Mr. Richard U. De Schutter is an Independent Director of the Company. He has served on the Board since January 2017. Prior to his retirement, Mr. De Schutter served as the Chairman and CEO of DuPont Pharmaceuticals Company from July 2000 until its acquisition by BristolMyers Squibb in October 2001. Mr. De Schutter was also a director and Chief Administrative Officer of Pharmacia Corporationrationration, which was created through the merger of Monsanto Company and Pharmacia Upjohn in 2000. Prior to this merger, Mr. De Schutter was a director, Vice Chairman and Chief Administrative Officer for Monsanto. From 1995 to 1999, he served as Chairman and CEO of G.D. Searle Co., Monsantos wholly owned pharmaceutical subsidiary. Mr. De Schutter earned a BS degree in 1963, and a MS Degree in Chemical Engineering in 1965 from the University of Arizona. Since 2007, Mr. De Schutter has served as a director of AuVen Therapeutics, a private equity company focused on the healthcare industry. He has also served as a director of Applied Silver, Inc., a private biotechnology company, since 2016. He previously served as Chairman of Incyte Corporation from 2003 to 2015, as Chairman of Durata Therapeutics Inc. from 2012 to 2014, Chairman of Navicure, Inc. from 2002 to 2016, and Chairman of Sprout Pharmaceuticals, Inc. from 2011 to 2015. Mr. De Schutter was also a director of Smith Nephew plc from 2001 to 2014, during which time he also served as the Lead Independent Director from 2011 to 2014. since 2017.
| Age | 79 |
| Tenure | 7 years |
| Address | 2150 St. ElzEar Boulevard West, Laval, QC, Canada, H7L 4A8 |
| Phone | 514 744 6792 |
| Web | https://www.bauschhealth.com |
Bausch Health Management Efficiency
The company has Return on Asset of 0.0382 % which means that on every $100 spent on assets, it made $0.0382 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (6.8652) %, meaning that it generated no profit with money invested by stockholders. Bausch Health's management efficiency ratios could be used to measure how well Bausch Health manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.61, whereas Return On Tangible Assets are projected to grow to (0.06). At present, Bausch Health's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 2.7 B, whereas Total Assets are forecasted to decline to about 14.9 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Lynda Reid | Evotec SE ADR | N/A | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| David Anstice | Alkermes Plc | 69 | |
| Grainne Troute | Evotec SE ADR | N/A | |
| David Pernock | Eagle Pharmaceuticals | 63 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Richard Edlin | Eagle Pharmaceuticals | 57 | |
| Hamish Stevens | Evotec SE ADR | N/A | |
| Floyd Bloom | Alkermes Plc | 80 | |
| Wendy Dixon | Alkermes Plc | 62 | |
| Nancy Wysenski | Alkermes Plc | 60 | |
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| Paul Mitchell | Alkermes Plc | 64 | |
| Nancy Snyderman | Alkermes Plc | 66 | |
| Anthony Quirk | Evotec SE ADR | N/A | |
| Norah Barlow | Evotec SE ADR | N/A | |
| Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Alain Schreiber | Eagle Pharmaceuticals | 58 | |
| Robert Breyer | Alkermes Plc | 73 | |
Management Performance
| Return On Equity | -6.87 | ||||
| Return On Asset | 0.0382 |
Bausch Health Companies Leadership Team
Elected by the shareholders, the Bausch Health's board of directors comprises two types of representatives: Bausch Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bausch. The board's role is to monitor Bausch Health's management team and ensure that shareholders' interests are well served. Bausch Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bausch Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| D Hale, Independent Director | ||
| Jeff Hartness, Commercial Access | ||
| John Barresi, Controller, VP | ||
| Sarah Kavanagh, Independent Director | ||
| Arthur Shannon, IR Contact Officer | ||
| Tage MD, Chief RD | ||
| William Humphries, Executive Vice President Company Group Chairman, Dermatology | ||
| Robert Butz, VP Affairs | ||
| Richard DeSchutter, Independent Director | ||
| Robert Hale, Independent Director | ||
| Paul Herendeen, Chief Financial Officer, Executive Vice President | ||
| Brett Icahn, Independent Director | ||
| Richard Schutter, Independent Director | ||
| Seana Carson, Executive Counsel | ||
| Josh Coyle, Senior Salix | ||
| Amy Wechsler, Independent Director | ||
| Graham Jackson, Senior Officer | ||
| Sam Will, Senior Vice President - Finance, Chief Accounting Officer, Controller | ||
| Robert Power, Independent Director | ||
| Thomas Vadaketh, Ex CFO | ||
| Argeris Karabelas, Independent Director | ||
| Kathleen Fitzpatrick, Senior Officer | ||
| Joseph Gordon, President and Co-Head Bausch + Lomb/International | ||
| Jiny MBA, Senior Medical | ||
| Christina Ackermann, Executive Vice President, General Counsel and Head of Commercial Operations | ||
| Thomas Ross, Lead Independent Director | ||
| Donald Pearl, Senior Dermatologics | ||
| Andrew Eschenbach, Independent Director | ||
| Mirza Dautbegovic, Senior COO | ||
| Joseph Papa, Chairman of the Board, Chief Executive Officer | ||
| Mark McKenna, President - Salix Pharmaceuticals | ||
| Elif McDonald, Director, Investor Relations | ||
| John Paulson, Independent Director | ||
| Steven Miller, Independent Director | ||
| Thomas Appio, Executive Vice President Company Group Chairman, International | ||
| Robert Spurr, President - Salix | ||
| Cees Heiman, Senior Canada | ||
| Russel Robertson, Independent Director |
Bausch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bausch Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.87 | ||||
| Return On Asset | 0.0382 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 25.77 B | ||||
| Shares Outstanding | 366.67 M | ||||
| Shares Owned By Insiders | 0.91 % | ||||
| Shares Owned By Institutions | 79.55 % | ||||
| Number Of Shares Shorted | 22.5 M | ||||
| Price To Earning | 9.26 X |
Bausch Health Investors Sentiment
The influence of Bausch Health's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Bausch. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Bausch Health's public news can be used to forecast risks associated with an investment in Bausch. The trend in average sentiment can be used to explain how an investor holding Bausch can time the market purely based on public headlines and social activities around Bausch Health Companies. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Bausch Health's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bausch Health's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Bausch Health's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Bausch Health.
Bausch Health Implied Volatility | 85.36 |
Bausch Health's implied volatility exposes the market's sentiment of Bausch Health Companies stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Bausch Health's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Bausch Health stock will not fluctuate a lot when Bausch Health's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bausch Health in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bausch Health's short interest history, or implied volatility extrapolated from Bausch Health options trading.
Pair Trading with Bausch Health
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bausch Health position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bausch Health will appreciate offsetting losses from the drop in the long position's value.Moving together with Bausch Stock
| 0.76 | A | Agilent Technologies Earnings Call This Week | PairCorr |
Moving against Bausch Stock
| 0.43 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Bausch Health could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bausch Health when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bausch Health - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bausch Health Companies to buy it.
The correlation of Bausch Health is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bausch Health moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bausch Health Companies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bausch Health can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Bausch Health Companies information on this page should be used as a complementary analysis to other Bausch Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Bausch Stock analysis
When running Bausch Health's price analysis, check to measure Bausch Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bausch Health is operating at the current time. Most of Bausch Health's value examination focuses on studying past and present price action to predict the probability of Bausch Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bausch Health's price. Additionally, you may evaluate how the addition of Bausch Health to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Bausch Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bausch Health. If investors know Bausch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bausch Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.115 | Earnings Share (1.62) | Revenue Per Share 23.998 | Quarterly Revenue Growth 0.098 | Return On Assets 0.0382 |
The market value of Bausch Health Companies is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Health's value that differs from its market value or its book value, called intrinsic value, which is Bausch Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bausch Health's market value can be influenced by many factors that don't directly affect Bausch Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bausch Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bausch Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bausch Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.